AllerGenis' mission is to develop precision diagnostic solutions that can help healthcare providers better assess and manage the well-being of millions of food allergy patients. Specializing in immunology and bioinformatics, we created a highly multiplexed analytical platform to address the limitations of current food allergy diagnostic tests.
AllerGenis develops precision, data driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. The company was founded out of a collaboration with Hugh Sampson MD, of the Icahn School of Medicine at Mount Sinai. AllerGenis’ technology platform is based on immunological research by Dr. Sampson, and leverages AllerGenis’ expertise in improving sensitivity of diagnostic tests. Mount Sinai Health System licensed its proprietary epitope mapping platform to AllerGenis, which the company is using to create the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain clinical insights.